LOS ANGELES–(BUSINESS WIRE)–The U.S. Food and Drug Administration approved use of Gilead’s HIV treatment medication, lenacapavir, for use to prevent HIV infection earlier today, an action which was followed by news that Gilead intends to price the HIV prevention medication at over $28,000 per patient, per year. AIDS Healthcare Foundation (AHF) President Michael Weinstein sharply criticized Gilead’s outrageous pricing in the following statement:
“By pricing lenacapavir at over $28K per patient, per year, Gilead is sacrificing potential worldwide control and elimination of HIV on the altar of its bottom line.”
“What could be an extraordinary game changer for HIV prevention is being completely undermined by Gilead’s greed. Charging $28,218 a year will drastically limit the availability of the drug. Gilead continues to feast on tens of billions of dollars, much of which is public funding for their HIV portfolio, at the expense of people living with or at risk of acquiring HIV. Gilead is sacrificing control of HIV on the altar of their bottom line.”
